Research Topics
| Eva BaecklundSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphomaEva Baecklund
Department of Rheumatology, University Hospital, Uppsala, Sweden
Arthritis Rheum 48:1543-50. 2003....
Rheumatoid arthritis and malignant lymphomasEva Baecklund
Department of Rheumatology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
Curr Opin Rheumatol 16:254-61. 2004..This review summarizes data on possible associations between RA and lymphomas, including different treatments and RA disease related risk factors...
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisEva Baecklund
Department of Rheumatology, Akademiska Hospital, Uppsala, Sweden
Arthritis Rheum 54:692-701. 2006..This study was undertaken to investigate which patients are at highest risk, and whether antirheumatic treatment is hazardous or protective...
Characteristics of diffuse large B cell lymphomas in rheumatoid arthritisEva Baecklund
Department of Rheumatology, Akademiska Hospital, Uppsala, Sweden
Arthritis Rheum 54:3774-81. 2006..This study was undertaken to investigate whether RA displays a specific association with any of the DLBCL subtypes...
Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritisEva Baecklund
Department of Rheumatology, University Hospital, Uppsala, Sweden
Br J Haematol 141:69-72. 2008..This supports that a majority of RA-DLBCL are of non-GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA-DLBCL...
Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA studyTuulikki Sokka
Jyvaskyla Central Hospital, Keskussairaalantie 19, 40620 Jyvaskyla, Finland
Arthritis Res Ther 12:R42. 2010..Recent reports suggest that the use of biologic agents offers potential for reduced work disability rates, but the conclusions are based on surrogate disease activity measures derived from studies primarily from Western countries...
